PPAR-γ agonists, mainly 15d-PGJ 2, reduce eosinophil recruitment following allergen challenge

Cellular Immunology

Volumn 273, Issue 1, 2012, Pages 23-29

  Farnesi de Assunção, Thais S ^a,b   Alves, Claudiney F ^b   Carregaro, Vanessa ^c   de Oliveira, Jhony R ^b   da Silva, Carlos A T ^a,b   Cheraim, Alessandra B ^b   Cunha, Fernando Q ^c   Napimoga, Marcelo H ^b,d  

^a FEDERAL UNIVERSITY OF TRIÂNGULO MINEIRO   (Brazil)

^b UNIVERSITY OF UBERABA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d SÃO LEOPOLDO MANDIC INSTITUTE AND RESEARCH CENTER   (Brazil)

Author keywords

15d PGJ2; Eosinophils; Inflammation; PPAR

Indexed keywords

15 DEOXY DELTA12,14 PROSTAGLANDIN J2; ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 17; INTERLEUKIN 23; INTERLEUKIN 33; INTERLEUKIN 5; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; IMMUNOMODULATION; LEUKOCYTE MIGRATION; LEUKOCYTE MIGRATION INHIBITION; MALE; MOUSE; NONHUMAN; PERITONEAL CAVITY; PRIORITY JOURNAL; TH2 CELL;

ALLERGENS; ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; EOSINOPHILIA; EOSINOPHILS; FLOW CYTOMETRY; IMMUNOGLOBULIN E; INFLAMMATION; INTERLEUKINS; LEUKOCYTE COUNT; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PPAR GAMMA; PROSTAGLANDIN D2; THIAZOLIDINEDIONES;

MUS;

EID: 84856013535     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2011.11.010     Document Type: Article

References (38)

1. Varga T., Nagy L. Nuclear receptors, transcription factors linking lipid metabolism and immunity: the case of peroxisome proliferator-activated receptor gamma. Eur. J. Clin. Invest. 2008, 38:695-707.
2. Díez-Dacal B., Pérez-Sala D. Anti-inflammatory prostanoids: focus on the interactions between electrophile signaling and resolution of inflammation. Sci. World J. 2010, 10:655-675.
3. Gilroy D.W., Lawrence T., Perretti M., Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat. Rev. Drug Discov. 2004, 3:401-416.
4. 12,14-prostaglandin J2 attenuates the development of acute and chronic inflammation. Mol. Pharmacol. 2002, 61:997-1007.
5. 2, reduces neutrophil migration via NO pathway. J. Immunol. 2008, 180:609-617.
6. 2 inhibits inflammatory hypernociception: involvement of peripheral opioid receptor. J. Pharmacol. Exp. Ther. 2008, 324:313-321.
7. 12,14-prostaglandin J2 induced-antinociception in rat temporomandibular joint. Neuroscience 2009, 163:1211-1219.
8. Hassumi M.Y., Silva-Filho V.J., Campos-Júnior J.C., Vieira S.M., Cunha F.Q., Alves P.M., Alves J.B., Kawai T., Gonçalves R.B., Napimoga M.H. PPAR-γ agonist rosiglitazone prevents inflammatory periodontal bone loss by inhibiting osteoclastogenesis. Int. Immunopharmacol. 2009, 9:1150-1158.
9. 2-loaded poly(D,L-lactide-co-glycolide) nanocapsules on inflammation. Br. J. Pharmacol. 2011, 162:623-632.
10. Belvisi M.G., Hele D.J., Birrell M.A. Peroxisome proliferator-activated receptor γ agonists as therapy for chronic airway inflammation. Eur. J. Pharmacol. 2006, 533:101-109.
11. Park S.J., Lee K.S., Kim S.R., Min K.H., Choe Y.H., Moon H., Chae H.J., Yoo W.H., Lee Y.C. Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation. J. Immunol. 2009, 183:3259-3267.
12. Ueki S., Adachi T., Bourdeaux J., Oyamada H., Yamada Y., Hamada K., Kanda A., Kayaba H., Chihara J. Expression of PPAR-γ in eosinophis and its functional role in survival and chemotaxis. Immunol. Lett. 2003, 86:183-189.
13. Matsuwaki Y., Ueki S., Adachi T., Oyamada H., Kamada Y., Yamaguchi K., Kanda A., Hamada K., Kayaba H., Chihara J. The synthetic PPAR-γ agonist troglitazone inhibits IL-5-induced CD69 upregulation and eosinophil-derived neurotoxin release from eosinophils. Pharmacology 2005, 74:169-173.
14. Woerly G., Honda K., Loyens M., Papin J., Auwerx J., Staels B., Capron M., Dombrowicz D. Peroxisome proliferator-activated receptor α and γ down-regulate allergic inflammation and eosinophil activation. J. Exp. Med. 2003, 198:411-421.
15. Fukui N., Honda K., Ito E., Ishikawa K. Peroxissonme proliferator-activated receptor γ negatively regulates allergic rhinitis in mice. Allergol. Int. 2009, 58:247-253.
16. Hammad H., Lambrecht B.N. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J. Allergy Clin. Immunol. 2006, 118:331-336.
17. Kurowska-Stolarska M., Kewin P., Murphy G., Russo R.C., Stolarski B., Garcia C.C., Komai-Koma M., Pitman N., Li Y., Niedbala W., McKenzie A.N., Teixeira M.M., Liew F.Y., Xu D. IL-33 induces antigen-specific IL-5+ T cells and promotes allergic-induced airway inflammation independent of IL-4. J. Immunol. 2008, 181:4780-4790.
18. Komai-Koma M., Xu D., Li Y., McKenzie A.N., McInnes I.B., Liew F.Y. IL-33 is a chemoattractant for human Th2 cells. Eur. J. Immunol. 2007, 37:2779-2786.
19. Li H., Bradbury J.A., Dackor R.T., Edin M.L., Graves J.P., DeGraff L.M., Wang P.M., Bortner C.D., Maruoka S., Lih F.B., Cook D.N., Tomer K.B., Jetten A.M., Zeldin D.C. Cyclooxygenase-2 regulates Th17 cell differentiation during allergic lung inflammation. Am. J. Respir. Crit. Care Med. 2011, 184:37-49.
20. Wakashin H., Hirose K., Maezawa Y., Kagami S., Suto A., Watanabe N., Saito Y., Hatano M., Tokuhisa T., Iwakura Y., Puccetti P., Iwamoto I., Nakajima H. IL-23 and Th17 cells enhance Th2-cell-mediated eosinophilic airway inflammation in mice. Am. J. Respir. Crit. Care Med. 2008, 178:1023-1032.
21. Peng J., Yang X.O., Chang S.H., Yang J., Dong C. IL-23 signaling enhances Th2 polarization and regulates allergic airway inflammation. Cell Res. 2010, 20:62-71.
22. Zingarelli B., Cook J.A. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock 2005, 23:393-399.
23. Cheraim A.B., Xavier-Elsas P., de Oliveira S.H., Batistella T., Russo M., Gaspar-Elsas M.I., Cunha F.Q. Leukotriene B4 is essential for selective eosinophil recruitment following allergen challenge of CD4+ cells in a model of chronic eosinophilic inflammation. Life Sci. 2008, 83:214-222.
24. Ueki S., Matsuwaki Y., Kayaba H., Oyamada H., Kanda A., Usami A., Saito N., Chihara J. Peroxisome proliferator-activated receptor-γ regulates eosinophil functions: a new therapeutic target for allergic airway inflammation. Int. Arch. Allergy Immunol. 2004, 134:30-36.
25. Rajakariar R., Hilliard M., Lawrence T., Trivedi S., Colville-Nash P., Bellingan G., Fitzgerald D., Yaqoob M.M., Gilroy D.W. Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15-deoxyDelta12 14 PGJ2. Proc. Natl. Acad. Sci. USA 2007, 104:20979-20984.
26. Denning G.M., Stoll L.L. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?. Pediatr. Pulmonol. 2006, 41:23-34.
27. Benayoun L., Letuve S., Druilhe A., Boczkowski J., Dombret M.C., Mechighel P., Megret J., Leseche G., Aubier M., Pretolani M. Regulation of peroxisome proliferator-activated receptor γ expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling. Am. J. Respir. Crit. Care Med. 2001, 164:1487-1494.
28. Lee K.S., Park S.J., Kim S.R., Min K.H., Jin S.M., Lee H.K., Lee Y.C. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor in a murine model of toluene diisocyanate-induced asthma. J. Immunol. 2006, 177:5248-5257.
29. Park S.J., Lee Y.C. Peroxisome proliferator-activated receptor as a novel therapeutic target in asthma. J. Asthma 2008, 45:1-8.
30. Cohn L., Elias J.A., Chupp G.L. Asthma: mechanisms of disease persistence and progression. Ann. Rev. Immunol. 2004, 22:789-815.
31. Takatsu K., Nakajima H. IL-5 and eosinophilia. Curr. Opin. Immunol. 2008, 20:288-294.
32. Lloyd C.M. IL-33 family members and asthma - bridging innate and adaptive immune responses. Curr. Opin. Immunol. 2010, 22:800-806.
33. Moussion C., Ortega N., Girard J.P. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel " alarmin" ?. PLoS ONE 2008, 3:e3331.
34. Smithgall M.D., Comeau M.R., Park-Yoon B.R., Kaufman D., Armitage R., Smith D.E. IL-33 amplifies both Th1- and Th2-type responses through its activity on human basophils, allergen-reactive Th2 cells, iNKT and NK Cells. Int. Immunol. 2008, 20:1019-1030.
35. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
36. Molet S., Hamid Q., Davoine F., Nutku E., Taha R., Pagé N., Olivenstein R., Elias J., Chakir J. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J. Allergy Clin. Immunol. 2001, 108:430-438.
37. Fujimura Y., Tachibana H., Yamada K. Peroxisome proliferator-activated receptor ligands negatively regulate the expression of the high-affinity IgE receptor Fc epsilon RI in human basophilic KU812 cells. Biochem. Biophys. Res. Commun. 2002, 297:193-201.
38. Miyazaki Y., Tachibana H., Yamada K. Inhibitory effect of peroxisome proliferator-activated receptor-gamma ligands on the expression of IgE heavy chain germline transcripts in the human B cell line DND39. Biochem. Biophys. Res. Commun. 2002, 295:547-552.